CTOs on the Move

Nautilus Biotechnology

www.nautilus.bio

 
Born from the founders` recognition that their diverse but complementary skills and experiences would enable them to successfully address challenges that others had not, the company set about solving a vexing problem: how to bring true proteomics to the world in a way that accelerates therapeutic development, dramatically improves medical diagnostics, and makes personalized and predictive medicine a reality. The extraordinary team at Nautilus represents a wide spectrum of disciplines and expertise, including: protein chemists, chip designers, molecular biologists, data scientists, material scientists, biophysicists, optical engineers, microfluidics engineers, bioinformaticists, software engineers, and more. Nautilus is positioned to revolutionize proteomics, transform the way ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.nautilus.bio
  • 201 Industrial Road Suite 310
    San Carlos, CA USA 94070
  • Phone: 206.333.2001

Executives

Name Title Contact Details

Funding

Nautilus Biotechnology raised $76M on 05/21/2020
Nautilus Biotechnology raised $200M on 06/10/2021

Similar Companies

ADS

ADS is a Pennsauken, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Phycotransgenics

Phycotransgenics, LLC is a Bloomington, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

PharmaForm

PharmaForm is a leading specialty contract development and manufacturing organization focusing on oral and transmucosal dosage forms. Founded in 1996, PharmaForm has built a reputation for delivering novel and innovative solutions to challenging problems

Prescos

Prescos is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Casebia

Bayer and CRISPR Therapeutics have entered into an agreement to create Casebia to discover, develop and commercialize new breakthrough therapeutics to cure blood disorders, blindness, and congenital heart disease. CRISPR Therapeutics will contribute its proprietary CRISPR-Cas9 gene-editing technology and intellectual property, while Bayer will make available its protein engineering expertise and relevant disease know-how. It is the first long-term strategic partnership of its kind to make a substantial investment in the development of target delivery systems in an effort to bring systemic in vivo CRISPR-Cas9 gene editing technology applications to patients.